, Volume 71, Issue 3–4, pp 273–277 | Cite as

Direct Injection of Plasma Samples and Micellar Chromatography of Procainamide and Its Metabolite N-Acetylprocainamide

  • Josep Esteve-Romero
  • Adria Martinavarro-Domínguez
  • José V. Marcos-Tomás
  • Enrique Ochoa-Aranda
  • Maria Rambla-Alegre
Full Short Communication


Micellar liquid chromatography was employed for the monitoring of procainamide and its metabolite N-acetylprocainamide using a C18 column. Sodium dodecyl sulphate (SDS) and modifier concentrations were optimised in order to obtain minimum analysis time, maximum sensitivity and good resolution. The optimum chromatographic conditions were as follows: flow rate 1 mL min−1, injection volume 20 μL, temperature at 25 °C, respectively. The mobile phase consisted of 0.05 M SDS-1% (v/v) butanol–phosphate buffer (10 mM, pH 7, 0.9%, w/v) NaCl using a detection wavelength at 280 nm. Validation studies were carried out according to the ICH guideline and included the determination of calibration curves (r 2 > 0.999), intra- and inter-day precisions (CV < 3.9%), robustness and interference studies, respectively. The recoveries in spiked serum samples were adjusted. Finally, the optimized method was applied to serum samples of patients treated with antiarrhythmics, and the results were compared with those given by a reference method where a good correlation was obtained.


Micellar liquid chromatography Direct injection Monitoring Procainamide N-Acetylprocainamide 



This study was part of Project P1-1B2006-12 funded by Fundació Caixa Castelló-Bancaixa-Universitat Jaume I, and CTQ2007-64473/BQU of the Ministry of Education and Science (MEC). We also wish to thank to this foundation, which has also supported the research grants of Devasish Bose. Maria Rambla-Alegre also wishes to thank the MEC for the FPU grant. Finally, we are grateful to the Council of Scientific and Industrial Research of New Delhi.


  1. 1.
    Valdes Jr R, Jortani Saeed A, Mihai G (1999). Antiarrhythmic drug monitoring. In: Standards of laboratory practice. Guidelines for therapeutic drug monitoring services. The National Academy of Clinical Biochemistry, pp 29Google Scholar
  2. 2.
    Vaughan Williams EM (1970) Classification of antiarrhythmic drugs. In: Sandoe E, Flensted-Jensen E, Olesen K II (eds) Symposium on cardiac arrhythmias. Stockholm, Sweden, p 449Google Scholar
  3. 3.
    Harrison DC (1985) Is there a rational basis for the modified classification of antiarrhythmic drugs? In: Morganroth J, Moore EN (eds) Cardiac arrhythmias: new therapeutic drugs and devices. Nijhoff, Boston, p 36Google Scholar
  4. 4.
    Peter R, Kowey MD (1998) Arch Intern Med 158:325–332CrossRefGoogle Scholar
  5. 5.
    Lopez-Perez JC, Moreno-Haro JL, Miranda-Leon MT (1989) Farm Clin 6:398–402Google Scholar
  6. 6.
    Stamp RJ, Mould GP, Muller C et al (1991) Ther Drug Monit 13:518–522CrossRefGoogle Scholar
  7. 7.
    O’Connell MT, Ratnaraj N, Elyas AA et al (1995) Ther Drug Monit 17:549–555CrossRefGoogle Scholar
  8. 8.
    Chetty M, Wilson JF (1999) 21:215–218Google Scholar
  9. 9.
    Jamali F, Alballa RS, Mehvar R et al (1988) Ther Drug Monit 10:91–96Google Scholar
  10. 10.
    Brandsteterova E, Ferenocova A (1999) Chem Listy 93:249–253Google Scholar
  11. 11.
    Riedmann M, Huber L (1986) Int Clin Prod Rev 5:16–19Google Scholar
  12. 12.
    Uges DRA (1985) Pharm Weekbl 120:732–741Google Scholar
  13. 13.
    Wong SHY, Marzouk N, Aziz O, Sheeran S (1987) J Liq Chromatogr Rel Technol 10:491–506CrossRefGoogle Scholar
  14. 14.
    Lotfi H, Debord J, Dreyfuss MF et al (1997) Ther Drug Monit 19:160–164CrossRefGoogle Scholar
  15. 15.
    Posluszny JV, Weinberger R (1988) Anal Chem 60:1953–1958CrossRefGoogle Scholar
  16. 16.
    Wu L, Wang Y (1989) Clin Chem 35:1355–1361Google Scholar
  17. 17.
    Lindberg R, Salonen JS, Laurikainen E (1982) Clin Chem 29:1572–1573Google Scholar
  18. 18.
    Proelss HF, Townsend TB (1986) Clin Chem 32:1311–1317Google Scholar
  19. 19.
    Interschick E, Rehorek A, Patscheke H, Becker W (1996) GIT Lab Med 19:150–153Google Scholar
  20. 20.
    Armstrong DW, Nome F (1981) Anal Chem 53:1662–1666CrossRefGoogle Scholar
  21. 21.
    Esteve-Romero J, Carda-Broch S, Gil-Agustí M, Capella Peiró ME, Bose D (2005) Trends Anal Chem 24:75–91CrossRefGoogle Scholar
  22. 22.
    Berthod A, García-Alvarez-Coque MC (2000) Micellar liquid chromatography. Marcel Dekker, New YorkGoogle Scholar
  23. 23.
    Torres-Lapasió JR, García-Alvarez-Coque MC, Baeza-Baeza JJ (1997) Anal Chim Acta 348:187–196CrossRefGoogle Scholar
  24. 24.
    Torres-Lapasió JR (2000) Michrom software. In: Berthod A, García-Alvarez-Coque MC (eds) Micellar liquid chromatography. Marcel Dekker, New YorkGoogle Scholar
  25. 25.
    Martinavarro-Domínguez A, Capella-Peiró ME, Gil-Agustí M, Marcos-Tomás JV, Esteve-Romero J (2002) Clin Chem 48:1696–1702Google Scholar
  26. 26.
    Capella-Peiró ME, Bose D, Martinavarro-Domínguez A, Gil-Agustí M et al (2002) J Chromatogr B 780:241–249CrossRefGoogle Scholar
  27. 27.
    Capella-Peiró ME, Gil-Agustí M, Martinavarro-Domínguez A, Esteve-Romero J (2002) Anal Biochem 309:261–268CrossRefGoogle Scholar
  28. 28.
    Gil-Agustí M, Capella-Peiró ME, Martinavarro-Domínguez A, Esteve-Romero J (2003) Chromatographia 57:51–57CrossRefGoogle Scholar
  29. 29.
    Esteve-Romero J, Capella-Peiró ME, Monferrer-Pons L, Gil-Agustí M (2003) Clin Chim Acta 348:69–77CrossRefGoogle Scholar
  30. 30.
    ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2 (R1) (2005). Website:

Copyright information

© Vieweg+Teubner | GWV Fachverlage GmbH 2010

Authors and Affiliations

  • Josep Esteve-Romero
    • 1
  • Adria Martinavarro-Domínguez
    • 2
  • José V. Marcos-Tomás
    • 3
  • Enrique Ochoa-Aranda
    • 2
  • Maria Rambla-Alegre
    • 1
  1. 1.Àrea de Química Analítica, QFAUniversitat Jaume ICastellóSpain
  2. 2.Servei Anàlisis ClíniquesHospital ProvincialCastellóSpain
  3. 3.Servei Anàlisis ClíniquesHospital Verge dels LlirisAlcoiSpain

Personalised recommendations